Yahes provided first quarter 2026 guidance of total revenues between $480 million and $490 million and adjusted EBITDA of $105 million to $110 million. Grow segment is forecast to be flat sequentially ...
Tina de los Reyes is the strategic biopharma development specialist for the Western US. With over 10 years of commercial experience in NGS and a Masters in Biomedical diagnostics, she specializes in ...
CRISPR gene editing and next-generation sequencing (NGS) have transformed clinical and life sciences research. CRISPR permits the selective targeting and editing of specific nucleotide sequences, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results